CORONA Remedies Limited has informed the Exchange about change in ManagementRe-appointment of M/s. Dhara Patel, peer reviewed Company Secretary Firm (ACS- 29198/C.P. No.-10979) as the Secretarial Auditor of the Company for a period of five consecutive years commencing from the Financial Year 2026-27
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CORONA Remedies Limited reported strong FY2026 results with standalone revenue of Rs. 1,403.18 Crores, up 17.3% from Rs. 1,196.42 Crores in FY2025. Net profit grew 24% to Rs. 184.85 Crores from Rs. 149.05 Crores. Basic EPS improved to Rs. 30.22 from Rs. 24.37. The Board recommended a final dividend of Rs. 10 per share (100% payout) with record date June 19, 2026. Key appointments include new statutory auditor Walker Chandiok & Co LLP for 5 years, re-appointment of secretarial auditor Dhara Patel, and re-appointment of Dr. Kirtikumar Mehta as Non-Executive Chairman for 5 years from April 2027. The company listed on NSE and BSE in December 2025 via IPO.
Positive signal: Strong revenue and profit growth indicates healthy business performance. Dividend payout and auditor changes reflect standard corporate governance actions. Shareholders can expect dividend approval at the ensuing AGM.